Maria Gavriatopoulou

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Ajai Chari, Dan T. Vogl, Maria Gavriatopoulou et al. · New England Journal of Medicine · 2019 · 673 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Sebastian Grosicki, Maryana Simonova, Ivan Špıčka et al. · The Lancet · 2020 · 324 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)

Meletios Α. Dimopoulos, Ramón García‐Sánz, Maria Gavriatopoulou et al. · Blood · 2013 · 207 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease

Efstathios Kastritis, Evangelos Terpos, Lia A. Moulopoulos et al. · Leukemia · 2012 · 159 citations

Medicine, Hematology, Pathology +17

Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose

Evangelos Terpos, Ioannis P. Trougakos, Maria Gavriatopoulou et al. · Blood · 2021 · 148 citations · Full text

Medicine, Immunology, Oncology +16